Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Meningitis Pipeline Drugs Market Report Overview
Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life-threatening. Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening.
The meningitis pipeline products market research report provides comprehensive information on the therapeutics under development for meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for meningitis and features dormant and discontinued projects.
| Key Targets | · Ergosterol
· GPI Anchored Wall Transfer Protein 1 · Chitin Synthase · Glycerol 3 Phosphate Oxidase · Lanosterol 14 Alpha Demethylase |
| Key MoA | · Ergosterol Inhibitor
· GPI Anchored Wall Transfer Protein 1 Inhibitor · Chitin Synthase Inhibitor · Lanosterol 14 Alpha Demethylase Inhibitor · Thymidylate Synthase Inhibitor |
| Key RoA | · Intramuscular
· Oral · Intravenous · Subcutaneous |
| Key Molecule Type | · Conjugate Vaccine
· Small Molecule · Vaccine · Inactivated Vaccine · Subunit Vaccine · Toxoid Vaccine |
| Leading Companies | · Chengdu Olymvax Biopharmaceuticals Inc
· Chongqing Zhifei Biological Products Co Ltd · Matinas BioPharma Holdings Inc · CanSino Biologics Inc |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Meningitis Pipeline Products Market - Competitive Landscape
A few of the leading companies in the meningitis pipeline products market are Chengdu Olymvax Biopharmaceuticals Inc., Chongqing Zhifei Biological Products Co Ltd, Matinas BioPharma Holdings Inc, CanSino Biologics Inc, Jiangsu Kunli Biopharmaceutical Co Ltd, LG Chem Ltd, Liaoning Cheng Da Biotechnology Co Ltd, and Linnaeus Bioscience Inc among others. Chengdu Olymvax Biopharmaceuticals Inc. is among the leading companies in the meningitis pipeline products market in 2022.
Chengdu Olymvax Biopharmaceuticals Inc: Olymvax Biopharmaceuticals Inc (Olymvax) is a pharmaceutical company that operates as a vaccine supplier. The Company provides novel vaccine development, traditional vaccine upgrading, and other services. Olymvax is headquartered in Sichuan, China.
Meningitis Pipeline Products Market Analysis by Companies, 2022(%)
Buy the Full Report to Know More About the Leading Meningitis Pipeline Products Market Players, Download a Free Report Sample
Meningitis Pipeline Products Market Segmentation by Targets
The key targets in the meningitis pipeline products market are ergosterol, GPI anchored wall transfer protein 1, chitin synthase, glycerol 3 phosphate oxidase, lanosterol 14 alpha demethylase, meningococcal capsular polysaccharide antigen, and thymidylate synthase. Ergosterol and GPI anchored wall transfer protein 1 are the leading targets in the meningitis pipeline drugs market.
Buy the Full Report for More Target Insights into The Meningitis Pipeline Products Market, Download a Free Report Sample
Meningitis Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the meningitis pipeline products market are ergosterol inhibitor, GPI anchored wall transfer protein 1 inhibitor, chitin synthase inhibitor, lanosterol 14 alpha demethylase inhibitor, and thymidylate synthase inhibitor. Ergosterol inhibitor and GPI anchored wall transfer protein 1 inhibitor are the leading MoAs in the pipeline market.
Buy the Full Report for More MoA Insights into the Meningitis Pipeline Products Market, and Download a Free Report Sample
Meningitis Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the meningitis pipeline products market are intramuscular, oral, intravenous, and subcutaneous. Intramuscular accounted for the highest number of meningitis drugs in development in terms of RoA in 2022.
Meningitis Pipeline Products Market Analysis by Routes of Administration, 2022(%)
Buy the Full Report More RoA Insights into The Meningitis Pipeline Products Market, Download a Free Report Sample
Meningitis Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the meningitis pipeline products market are conjugate vaccine, small molecule, vaccine, inactivated vaccine, subunit vaccine, and toxoid vaccine. The conjugate vaccine is the leading molecule type in the meningitis pipeline drugs market.
Meningitis Pipeline Products Market Analysis by Molecule Types
Buy the Full Report More Molecule Type Insights into the Meningitis Pipeline Products Market, Download a Free Report Sample
Meningitis Pipeline Products Market – Featured and Press Releases
- On Oct 23, 2022, Matinas BioPharma to present new MAT2203 (oral amphotericin B) data during IDWeek 2022.
- On Oct 21, 2022, Matinas BioPharma announced positive interim data from the phase 2 EnACT trial of MAT2203 for the treatment of cryptococcal meningitis, exceeding the primary endpoint threshold; patient survival in all-oral cohort 4 regimen currently 90%.
Segments Covered in the Report
Meningitis Pipeline Products Target Outlook
- Ergosterol
- GPI Anchored Wall Transfer Protein 1
- Chitin Synthase
- Glycerol 3 Phosphate Oxidase
- Lanosterol 14 Alpha Demethylase
Meningitis Pipeline Products MoA Outlook
- Ergosterol Inhibitor
- GPI Anchored Wall Transfer Protein 1 Inhibitor
- Chitin Synthase Inhibitor
- Lanosterol 14 Alpha Demethylase Inhibitor
- Thymidylate Synthase Inhibitor
Meningitis Pipeline Products RoA Outlook
- Intramuscular
- Oral
- Intravenous
- Subcutaneous
Meningitis Pipeline Products Molecule Type Outlook
- Conjugate Vaccine
- Small Molecule
- Vaccine
- Inactivated Vaccine
- Subunit Vaccine
- Toxoid Vaccine
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of meningitis.
- The pipeline guide reviews pipeline therapeutics for meningitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in meningitis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates meningitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for meningitis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for meningitis.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the meningitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Chengdu Olymvax Biopharmaceuticals Inc
Chongqing Zhifei Biological Products Co Ltd
Jiangsu Kunli Biopharmaceutical Co Ltd
LG Chem Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Linnaeus Bioscience Inc
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Pfizer Inc
Serum Institute of India Pvt Ltd
TGV Therapeutics
Yisheng Biopharma Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the meningitis pipeline products market?
The key targets in the meningitis pipeline products market are ergosterol, GPI anchored wall transfer protein 1, chitin synthase, glycerol 3 phosphate oxidase, lanosterol 14 alpha demethylase, meningococcal capsular polysaccharide antigen, and thymidylate synthase.
-
What are the key mechanisms of action in the meningitis pipeline products market?
The key MoA in the meningitis pipeline products market are ergosterol inhibitors, GPI anchored wall transfer protein 1 inhibitor, chitin synthase inhibitor, lanosterol 14 alpha demethylase inhibitor, and thymidylate synthase inhibitor.
-
What are the key routes of administration in the meningitis pipeline products market?
The key RoA in the meningitis pipeline products market are intramuscular, oral, intravenous, and subcutaneous.
-
What are the key molecule types in the meningitis pipeline products market?
The key molecule types in the meningitis pipeline products market are conjugate vaccine, small molecule, vaccine, inactivated vaccine, subunit vaccine, and toxoid vaccine.
-
Which are the leading companies in the meningitis pipeline products market?
Some of the leading companies in the meningitis pipeline products market are Chengdu Olymvax Biopharmaceuticals Inc., Chongqing Zhifei Biological Products Co Ltd, Matinas BioPharma Holdings Inc, CanSino Biologics Inc, Jiangsu Kunli Biopharmaceutical Co Ltd, LG Chem Ltd, Liaoning Cheng Da Biotechnology Co Ltd, and Linnaeus Bioscience Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Infectious Disease reports